# It Took a Text From Joe Rogan. Now Psychedelics Are a Federal Research Priority. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/psychedelic-federal-research-priority-2026/ > **Published:** 2026-04-18T22:36:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:18:45-04:00 > **Clinical Summary:** Explore how the psychedelic federal research priority is reshaping clinical studies and policy in 2026, enabling new treatment possibilities. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchMental HealthNeurology Why This Matters Rescheduling cannabis from Schedule I to Schedule III would remove federal barriers to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and allow physicians to prescribe cannabis-derived medications with fewer regulatory constraints, potentially enabling evidence-based treatment protocols for conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) and chemotherapy-induced nausea. This policy shift directly impacts clinician ability to access research data, conduct trials, and make informed recommendations to patients currently relying on unregulated products or avoiding cannabis due to legal liability concerns. The increased federal priority for psychedelic research similarly signals potential future availability of psilocybin and ibogaine treatments through clinical channels rather than underground markets, giving patients legal, monitored access to emerging therapies for treatment-resistant depression and addiction disorders. Clinical Summary A recent executive order has directed the Attorney General to reschedule cannabis from Schedule I to Schedule III at the federal level, which would significantly reduce regulatory barriers to [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and potentially improve access for patients, though DEA implementation remains pending as of early 2026. Concurrent renewed attention to psychedelic compounds, highlighted by high-profile media coverage, has elevated these substances as federal research priorities alongside cannabis. The rescheduling of cannabis to Schedule III would allow qualified researchers to conduct clinical trials with fewer restrictions and enable physicians to prescribe cannabis-derived medications more readily, while also potentially facilitating comparative effectiveness research and standardization of dosing and formulations. These regulatory changes reflect a broader shift in federal policy toward recognizing the therapeutic potential of cannabis and psychedelics, which could accelerate the translation of preclinical findings into clinically actionable evidence for treating conditions such as chronic pain, anxiety, and treatment-resistant psychiatric disorders. Clinicians should monitor DEA action on this rescheduling directive and prepare to engage with updated clinical guidelines as research opportunities expand and evidence for cannabis and psychedelic therapies accumulates in coming months. Dr. Caplan’s Take “What we’re seeing with the federal rescheduling effort is long overdue recognition that cannabis and psychedelics deserve the same rigorous research infrastructure we’ve applied to other medicines, but I’d caution my colleagues that media attention, however helpful for policy momentum, doesn’t substitute for the clinical evidence we still need to safely integrate these compounds into standard practice.” Clinical Perspective The shifting federal stance on psychedelics and cannabis scheduling reflects growing momentum for research into these substances, yet clinicians should recognize that rescheduling discussions and research prioritization do not automatically translate into evidence-based clinical guidance or approved therapeutic pathways. While the potential therapeutic applications of psychedelics like psilocybin and ibogaine, along with cannabis derivatives, warrant serious investigation—particularly for treatment-resistant depression and certain addiction disorders—the evidence base remains preliminary and heterogeneous, complicated by decades of research restrictions, publication bias toward positive findings, and the challenge of conducting rigorous placebo-controlled trials with subjectively potent experiences. The gap between policy momentum (driven partly by cultural figures and media attention) and robust clinical evidence is substantial; even if cannabis moves to Schedule III, clinicians will still lack clear dosing guidelines, standardized formulations, and head-to-head efficacy data compared to established treatments. Healthcare providers should 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+It+Took+a+Text+From+Joe+Rogan.+Now+Psychedelics+Are+a+Federal+Research+Priority.+%40drcaplan&url=https%3A%2F%2Fhightimes.com%2Fnews%2Fpolitics%2Fit-took-a-text-from-joe-rogan-now-psychedelics-are-a-federal-research-priority%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fhightimes.com%2Fnews%2Fpolitics%2Fit-took-a-text-from-joe-rogan-now-psychedelics-are-a-federal-research-priority%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+It+Took+a+Text+From+Joe+Rogan.+Now+Psychedelics+Are+a+Federal+Research+Priority.+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fhightimes.com%2Fnews%2Fpolitics%2Fit-took-a-text-from-joe-rogan-now-psychedelics-are-a-federal-research-priority%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://hightimes.com/news/politics/it-took-a-text-from-joe-rogan-now-psychedelics-are-a-federal-research-priority/](https://hightimes.com/news/politics/it-took-a-text-from-joe-rogan-now-psychedelics-are-a-federal-research-priority/) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I](https://cedclinic.com/4-fluoroamphetamine-schedule-i-placement/) CED Clinic Blog[Cannabis Nebulizer Patent (US 2017/0281701): Evidence Analysis](https://cedclinic.com/cannabis-nebulizer-patent-analysis-2017-0281701/) Evidence Watch[Endocannabinoid System & Child Autism Risk: New Evidence](https://cedclinic.com/peripregnancy-cannabis-exposure-autism-risk-new-evidence/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [President Trump signs executive order encouraging research on psychedelic drugs – WCTV](https://cedclinic.com/psychedelic-executive-order-research/) Learn about the executive order that boosted federal research efforts on psychedelic drugs, marking a significant policy shift. [Read More](https://cedclinic.com/psychedelic-executive-order-research/) [DEA Judge Issues Order Laying Out Process For Marijuana Rescheduling Hearing Starting …](https://cedclinic.com/dea-marijuana-rescheduling-procedural-order-hearing/) Explore the DEA's procedural steps for marijuana rescheduling, which parallels shifts in psychedelic research priorities. [Explore Details](https://cedclinic.com/dea-marijuana-rescheduling-procedural-order-hearing/) [The Realities of Rescheduling Medical Cannabis | Rockefeller Institute of Government](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) Understand the complexities and implications of rescheduling medical cannabis, relevant to broader drug policy reforms. [Learn More](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).